139 related articles for article (PubMed ID: 35875691)
1. Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib.
Banasavadi-Siddegowda YK; Namagiri S; Otani Y; Sur H; Rivas S; Bryant JP; Shellbourn A; Rock M; Chowdhury A; Lewis CT; Shimizu T; Walbridge S; Kumarasamy S; Shah AH; Lee TJ; Maric D; Yan Y; Yoo JY; Kumbar SG; Heiss JD; Kaur B
Neurooncol Adv; 2022; 4(1):vdac095. PubMed ID: 35875691
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Otani Y; Sur HP; Rachaiah G; Namagiri S; Chowdhury A; Lewis CT; Shimizu T; Gangaplara A; Wang X; Vézina A; Maric D; Jackson S; Yan Y; Zhengping Z; Ray-Chaudhury A; Kumar S; Ballester LY; Chittiboina P; Yoo JY; Heiss J; Kaur B; Banasavadi-Siddegowda YK
Neuro Oncol; 2021 Sep; 23(9):1481-1493. PubMed ID: 33556161
[TBL] [Abstract][Full Text] [Related]
3. PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.
Banasavadi-Siddegowda YK; Russell L; Frair E; Karkhanis VA; Relation T; Yoo JY; Zhang J; Sif S; Imitola J; Baiocchi R; Kaur B
Oncogene; 2017 Jan; 36(2):263-274. PubMed ID: 27292259
[TBL] [Abstract][Full Text] [Related]
4. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
5. PRMT5 as a druggable target for glioblastoma therapy.
Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B
Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602
[TBL] [Abstract][Full Text] [Related]
6. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
Yan F; Alinari L; Lustberg ME; Martin LK; Cordero-Nieves HM; Banasavadi-Siddegowda Y; Virk S; Barnholtz-Sloan J; Bell EH; Wojton J; Jacob NK; Chakravarti A; Nowicki MO; Wu X; Lapalombella R; Datta J; Yu B; Gordon K; Haseley A; Patton JT; Smith PL; Ryu J; Zhang X; Mo X; Marcucci G; Nuovo G; Kwon CH; Byrd JC; Chiocca EA; Li C; Sif S; Jacob S; Lawler S; Kaur B; Baiocchi RA
Cancer Res; 2014 Mar; 74(6):1752-65. PubMed ID: 24453002
[TBL] [Abstract][Full Text] [Related]
7. FKBP38 Regulates Self-Renewal and Survival of GBM Neurospheres.
Dowling AL; Walbridge S; Ertekin C; Namagiri S; Camacho K; Chowdhury A; Bryant JP; Kohut E; Heiss JD; Brown DA; Kumbar SG; Banasavadi-Siddegowda YK
Cells; 2023 Nov; 12(21):. PubMed ID: 37947640
[TBL] [Abstract][Full Text] [Related]
8. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
10. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
11. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
[TBL] [Abstract][Full Text] [Related]
12. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
13. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
14. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
[TBL] [Abstract][Full Text] [Related]
15. Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling.
Chung J; Karkhanis V; Baiocchi RA; Sif S
J Biol Chem; 2019 May; 294(19):7692-7710. PubMed ID: 30885941
[TBL] [Abstract][Full Text] [Related]
16. Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Fan Z; He L; Li M; Cao R; Deng M; Ping F; Liang X; He Y; Wu T; Tao X; Xu J; Cheng B; Xia J
Neoplasia; 2020 Nov; 22(11):617-629. PubMed ID: 33045527
[TBL] [Abstract][Full Text] [Related]
17. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
18. The protein arginine methyltransferase PRMT5 regulates Aβ-induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer's disease.
Quan X; Yue W; Luo Y; Cao J; Wang H; Wang Y; Lu Z
J Neurochem; 2015 Sep; 134(5):969-77. PubMed ID: 26086249
[TBL] [Abstract][Full Text] [Related]
19. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
